DECREASES IN CORPOREAL VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION PRECEDE VASOREACTIVITY CHANGES IN CHOLESTEROL FED RABBITS
- 1 April 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 173 (4) , 1418-1422
Abstract
We determined temporal changes in vasoreactivity and angiogenic growth factor levels in corporeal tissue at varying time points after the induction of hypercholesterolemia in rabbits. A total of 42 New Zealand White rabbits were fed a 1% cholesterol (8 per group) or normal (6 per group) diet for 2, 4.5 or 7.5 weeks. Vascular endothelial growth factor (VEGF) mRNA expression in corpus cavernosum was assessed by real-time polymerase chain reaction analyses for the 3 isoforms VEGF121, VEGF165 and VEGF189. Isometric tension studies were performed and dose response curves were generated to evaluate endothelial dependent and endothelial independent vasoreactivity. Real-time polymerase chain reaction analysis showed 2.2 to 2.5 and 1.5 to 2.7-fold decreases in VEGF121 and VEGF165, respectively, in the corporeal tissues of the high cholesterol group vs the normal diet group at the 2 week time point. At 2 weeks VEGF189 was unchanged but it was decreased 1.5 to 2-fold at 4.5 weeks. Acetylcholine isometric tension studies revealed no difference in mean ED50 (–log [M]) ± SD until 7.5 weeks of high cholesterol diet (5.10 ± 0.64 vs 3.95 ± 1.35, p = 0.0269). The response to sodium nitroprusside was not statistically different at any time point. Endothelial cell and smooth muscle content were decreased for the high cholesterol vs normal diet at 4.5 weeks (endothelial only) and 7.5 weeks (each cell). Alterations in corporeal tissue levels of VEGF occur before abnormalities in vasoreactivity. The results suggest that VEGF has a role in normal vasoreactivity in corporeal tissue and, thereby, in normal erectile function.Keywords
This publication has 19 references indexed in Scilit:
- Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetesJournal of Molecular Endocrinology, 2003
- VASCULAR ENDOTHELIAL GROWTH FACTOR RESTORES CORPOREAL SMOOTH MUSCLE FUNCTION IN VITROJournal of Urology, 2001
- Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary studyInternational Journal Of Impotence Research, 2000
- The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.Nature Medicine, 2000
- Erectile DysfunctionNew England Journal of Medicine, 2000
- Expression of Messenger Ribonucleic Acid Splice Variants for Vascular Endothelial Growth Factor in the Penis of Adult Rats and Humans1Biology of Reproduction, 1999
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995
- Objective Quantification of Cavernous Endothelium in Potent and Impotent MenJournal of Urology, 1995
- Nitric Oxide: A Physiologic Mediator of Penile ErectionScience, 1992
- Regulatory Functions of the Vascular EndotheliumNew England Journal of Medicine, 1990